Introduction
Most of the approaches to modulate the immune responses are currently achieved either by systemic treatments employing drugs and recombinant molecules, or experimental germinal and somatic gene transfer. In vivo or ex vivo viral methods are the most commonly used somatic gene transfers. However, viral methods exhibit a safety concern relative to potential insertional mutagenesis into the host genome and potential immunological effects. As a result of these drawbacks, attempts to develop physical methods able to deliver exogenous genes to a target tissue are in progress. Electroporation has been used for many years to load genetic material into cells in vitro. [1] [2] [3] [4] The use of electric fields to deliver genes in vivo is more recent than in vitro applications. Tissues for which highly efficient gene transfer is sought include tumors, various epithelia or endothelia, and organs such as the liver, heart, brain, and skeletal muscle. The latter is used for the local (for instance, angiogenic factors) or systemic (for instance, erythropoietin, clotting factors, anti-inflammatory cytokines, etc) delivery of molecules [5] [6] [7] [8] [9] [10] [11] and also for vaccination. 12 Electric pulses have been used to transfer DNA in vivo to skin, 13 to liver, 14, 15 and to tumor cells. 16 Aihira et al 17 and Mir et al 18, 19 simultaneously reported efficient plasmid DNA electrotransfer into muscle fibers.
To use muscle as a secretory tissue was shown to be efficient also when DNA plasmid was electrotransfered 9, 11, [20] [21] [22] and for vaccination. 12 Lastly, secreted transgenic proteins encoded by the electrotransfered DNA plasmids are able to induce physiological effects. 23 Nevertheless, no experimental trials have been performed to target lymphoid tissues through an electrotransfer approach.
The aim of the present study was to perform in vivo gene electrotransfer in one of the most important lymphoid organs, the spleen, in order to modulate the systemic immuno-inflammatory response to environmental stimuli. It has been largely documented that this second lymphoid organ is involved in the initiation of immune responses, bringing together antigen and naive lymphocytes in highly organized microenvironments that support the antigen-specific clonal expansion of these cells and their differentiation into memory-effector subsets. Spleen displays specialized vascular adaptations designed to recruit lymphocytes and to filter the blood, collecting antigens that have been introduced into the vascular system. Moreover, because of its solid morphology and the continuous trafficking of cells through it, the spleen is an interesting functional and anatomic target organ of electrotransfer of genes. We found intrasplenic gene electrotransfer to be an efficient gene transfer method as compared to intramuscular gene transfer. Intrasplenic gene transfer can also be used to deliver secreted molecules. The transfected cells were expected to be mostly splenic resident cells. However, it appeared that transfected cells could recirculate outside of the spleen, thus indicating that lymphoid cells were transfected as well. Indeed, we showed that T cells could be transfected in vivo. We finally provide evidence that this procedure by itself does not impair immune responses.
Results and discussion

Optimization of electric parameters
In pilot experiments (data not shown), C57Bl/6 mice were submitted to an intrasplenic electrotransfer (ISE) with a pCMV-Luc plasmid and the luciferase activity was measured on spleen lysates 3 days after gene transfer. First, we found that clamping the vasculature of the spleen yielded a 4-time better gene transfer efficiency most likely because (i) the plasmid was not washed away by the blood flow and (ii) the spleen was electrically isolated, and thus the electric field did not spread. We found that the optimal amount of DNA was 15 mg diluted in 30 ml of PBS. Injection of 5 mg was twofold less efficient than injecting 15 mg, while increasing the amount of plasmid over 15 mg did not yield higher gene transfer. Injection in a volume of 50 ml resulted in a leakage of the solution out of the spleen while performing the injection and resulted in a two-to three-fold less efficient gene transfer. A very low efficiency was obtained with a volume of 10 ml, which might indicate that this smaller volume did not spread sufficiently in the spleen. The optimal number of pulses was found to be 8 (tested from 1 to 15). Thus, in all the subsequent experiments, the vasculature of the spleen was clamped, 15 mg of plasmid was diluted in 30 ml of PBS, and eight pulses were applied.
We evaluated the influence of the pulse length (0.1-60 ms), of the voltage intensity (500-1200 V/cm), and of the pulse frequency (1 or 2 Hz), all electric parameters that can influence efficiency of gene transfer. Control groups were submitted either to ISE without plasmid or received an intrasplenic injection of the pCMV-Luc plasmid without electroporation. As shown in Figure 1 , the injection of plasmid without electroporation resulted in a weak but detectable intrasplenic luciferase expression. Voltage conditions above 800 V/cm did not improve transfection efficiency and were associated with tissue damages (partial or complete necrosis of the spleen; data not shown), especially when pulse length was longer. At 500 V/cm, the spleen tissue analyzed by standard histology was not damaged (data not shown). Voltage o500 V/cm or pulse length o20 ms resulted in 1-2 log lower gene transfer efficiency (data not shown). At 500 V/cm, we found that 20 ms was the optimal pulse length. The frequency was not found to be a critical parameter for intrasplenic gene transfer efficiency, but 2 Hz impulses resulted in a lower variability ( Figure 1 and data not shown).
Intrasplenic vs intramuscular gene transfer efficiency
The intramuscular electrotransfer (IME) was used in the present study as a reference method of in vivo gene transfer. Mice were thus submitted to IME or ISE with the pCMV-Luc plasmid with the respective optimal electroporation parameters. It has recently been shown that if the light emitted in vivo from the luciferaseexpressing cells is sufficient, it can be detected in anesthetized animals through the tissues with a sensitive CCD camera. [24] [25] [26] We thus used this new method to visualize the luciferase activity in vivo and we also used the standard procedure to measure it on tissue samples. Indeed, we could easily detect the luciferase activity after an IME (Figure 2a) . However, an intrasplenic spot signal could be detected only after directly exposing the spleen (Figure 2b ), thus indicating that the level of transfection achieved with ISE was lower than that of IME.
As shown in Figure 2c , the standard luciferase activity measurement performed on tissue samples confirmed that ISE was less efficient than IME, but by only one log. Given that IME is an especially efficient gene transfer method, our results show that ISE is also an efficient transfection method.
The variability of expression levels was similar between IME and ISE and might be related to the injection point. The tissue compartment in which the plasmid solution is injected, in particular relative to the electrode placement, is difficult to control with precision and might be critical. New devices that can deliver both the plasmid and the electric pulses might improve the reproducibility of in vivo gene electrotransfers.
Transfected cells are still present in the spleen 30 days after transfection
Having established that ISE can be used to transfect spleen cells in vivo, we next intended to determine the Figure 1 Influence of electric-pulse parameters on the expression of splenic luciferase. A single intrasplenic injection of 15 mg pCMV-Luc in 30 ml of PBS was performed in anesthetized C57Bl/6 mice. The luciferase activity was measured on spleen homogenate 3 days after electrotransfer. Different pulse length, voltage intensity, and frequency were tested. Each point represents the value for one mouse and the bars represent the average for each group, n: number of mice per group. *Po0.05 vs the group '8 Â 500 V/cm-20 ms-2 Hz'.
In vivo gene electrotransfer of spleen cells E Tupin et al length of period during which transfected cells could still be detected in the spleen. Mice were submitted to ISE with the pCMV-Luc plasmid and were killed 3, 6, 8, or 30 days later. As shown in Figure 3 , the luciferase activity in the spleen decreased dramatically after 6 days, but was still easily detectable after 30 days. This decrease might be because of the fact that the transfection is transitory and/or that transfected cells had left the spleen.
Transfected spleen cells can recirculate
To analyze whether transfected cells were sequestered in the spleen or whether they could leave the spleen and home to other organs, mice were submitted to ISE with the pCMV-Luc plasmid and the luciferase activity was measured in various lymphoid and nonlymphoid organs 3, 8, and 30 days post-transfection. Given that luciferase activity was analyzed in various organs, results were normalized by the protein concentration to allow comparison of luciferase expression levels between tissues. In the previous experiments, luciferase readout background following electroporation without plasmid was sometimes abnormally high resulting in false positive values. This could have been a confounding effect in the present experiment for which levels of luciferase activity in extrasplenic tissue samples were expected to be low. Thus, we decided to include, as controls, electrotransfer with an empty plasmid rather than injection of a luciferase-encoding plasmid without electroporation.
Once again, the luciferase activity decreased rapidly in the spleen (Figure 4) . However, as soon as 3 days posttransfection, transfected cells could be detected in various lymphoid organs. Indeed, luciferase activity was detectable in the axillary, mandibulary, para-aortic, and inguinal lymph nodes. At variance, it could not be detected in the mesenteric lymph nodes or Peyer's patches. Luciferase activity was also detected in the thymus and weakly in the lungs after 3 days. In all the positive organs, the luciferase activity decreased after 3 days indicating that the decrease in the luciferase activity observed in the spleen could be explained only partially by the fact that the transfected cells had left the spleen. This decrease is also likely owing to the fact that ISE yields mainly transitory transfection. That transfected spleen cells could be found in other lymphoid organs implied that this transfection method could transfect lymphoid cells. We could never detect any luciferase activity in the blood. This might indicate that the detection method is not sensitive enough to detect few circulating transfected cells or that transfected cells were homing to other lymphoid organs through the lymph circulation. Of note, in experiments in which the luciferase-encoding plasmid was injected in the spleen without electroporation, the luciferase activity assessed Figure 2 ISE vs IME. (a) and (b) Three days after IME (a: eight pulses of 20 ms, 200 V/cm, 2 Hz, 15 mg/30 ml/muscle) or ISE (b: eight pulses of 20 ms, 500 V/cm, 2 Hz, 15 mg/30 ml/spleen) with the pCMV-Luc plasmid, the mice (C57Bl/6) received an ip injection of luciferin. One image was acquired under low light to grab the silhouette of the mouse and a second image was acquired in the dark 5 min after the luciferin injection to detect the photons emitted from the transfected cells through the tissues. For the second image, the photons were captured during 5 min.The two images were then overlapped to determine the topology of transfected cells. For ISE (b), the spleen had to be exposed in order to detect the photons. (c) Three days after in vivo electroporation with the pCMV-Luc plasmid, the mice were killed and the luciferase activity was assayed in tissue lysates from the electrotransfered tibial cranial skeletal muscle when an IME was applied or from the spleen when an ISE was performed, n: number of mice per group. Figure 3 Time course of splenic luciferase gene expression. C57Bl/6 mice were submitted to an ISE (eight pulses of 20 ms, 500 V/cm, 2 Hz, 15 mg/ 30 ml/spleen) and were killed at the indicated time points. The luciferase activity was measured on spleen lysates. Each point represents the value for one mouse and the bars represent the average for each group, n: number of mice per group. All differences between groups were statistically significant (P o 0.01) except between groups of 8 and 30 days.
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Intrasplenic gene transfer works also for secreted products
Luciferase is an intracellular enzyme. However, given that ISE could be used to transfect lymphoid cells, this method might be useful to transfect cells with constructions coding for secreted products. This might be a way to use transfected cells as vectors to deliver cytokines, growth factors, or other molecules to a given site. Thus, we next asked whether ISE could also be used to transfect cells with plasmids coding for secreted products. For these experiments, we used the pCMV-SeAP plasmid encoding the alkaline phosphatase and the pCMV-IFNg plasmid. As shown in Figure 5 , a strong alkaline phosphatase activity was detected in the blood 3 days after ISE with the pCMV-SeAP plasmid, which increased at day 6 and rapidly declined after day 8. As previously shown with the luciferase reporter gene, the IME was more efficient than the ISE and lasted longer since alkaline phosphatase activity was still detectable at day 30. Interestingly, pCMV-IFNg plasmid electrotransfer resulted in a similar kinetic pattern of expression of IFNg as that of alkaline phosphatase ( Figure 5 ). Furthermore, 6 days post-transfection, ISE and IME resulted in equivalent levels of circulating transgenic secreted proteins. The time course data for the secreted proteins IFNg and alkaline phosphatase ( Figure 5 ) confirmed that transgene expression declines between days 6 and 8 Figure 4 Detection of transfected cells outside of the spleen. C57Bl/6 mice were submitted to an ISE (8 pulses of 20 ms, 500 V/cm, 2 Hz, 15 mg/30 ml/ spleen) with an empty vector (&) or with the pCMV-Luc plasmid (J) and were killed at the indicated time points. The luciferase activity was measured on spleen, axillary and mandibullary lymph nodes, para-aortic and inguinal lymph nodes, thymus, Peyer's patches, blood, and lung lysates. Each point represents the value for one mouse. Results are expressed in RLU/ug proteins. The table indicates the number of mice for each group at each time point. *Po0.05 pCMV-Luc vs pCMV-empty.
In vivo gene electrotransfer of spleen cells E Tupin et al following plasmid delivery by ISE. The decline was indeed similar to what was observed for the luciferase, an intracellular product ( Figure 3 ). The consistency of the timing and magnitude of this decline is apparently a characteristic feature of gene expression following ISE delivery. Surprisingly, while the peak luciferase activity after ISE was reached at day 3 post-transfection, it was reached at day 6 with the pCMV-IFNg and pCMV-SeAP plasmids. Also, the expression of luciferase was 410 times higher in the muscle after an IME than in the spleen after an ISE, while the serum levels of SeAP were only 3-8 times higher after an IME than an ISE. Several factors may have contributed to these apparent discrepancies: (i) the stability of the various transgenic proteins is likely to be different; (ii) the muscle may present a greater capacity to express intracellular proteins, while spleen cells would express secreted proteins more efficiently; (iii) endogenous alkaline phosphatase and IFNg might be expressed differentially in the spleen and the muscle following electrotransfers; (iv) SeAP and IFNg might reach the blood flow with different kinetics depending on whether they are expressed from the muscle or the spleen. Of note, differences in gene expression levels between SeAP and erythropoietin were reported by Mennuni et al 27 despite the fact that both proteins are secreted; and (v) the sensitivity of the detection assays might be different.
Immune response to the transgene products
An immune response directed to epitopes of transgene products is a general concern to gene therapy. Interestingly, when a plasmid coding for luciferase is injected into the muscle tissue, stability of expression is observed for more than 9 months indicating that, at least for this transgene, intramuscular expression does not trigger an immune response that would extinguish its expression. The stability of expression is most likely related to the slow turnover of the skeletal muscle cells.
The immune response directed against the transgene product can conceptually be stronger after a spleen electrotransfer than after electrotransfer in nonlymphoid target organs. We thus assessed over time the antibody titer to IFNg and to alkaline phosphatase after ISE and IME of the pCMV-IFNg and pCMV-SeAP plasmids. In this setting, the transgenic murine IFNg is a homologous protein, while the transgenic human alkaline phosphatase is a heterologous protein. Both ISE and IME slightly and similarly increased the anti-IFNg IgG level at day 3 but not the anti-SeAP IgG level ( Figure 5 ). It is tempting to discuss the fact that mice developed antibodies against a homologous protein (mouse IFNg) but not against a heterologous protein (human SeAP). However, this should be tempered by the fact that (i) the anti-IFNg antibody levels reached were very low and (ii) the nucleotide sequence of the human AP presents B60% identity with the sequence of the murine AP and, thus, human AP is not expected to be highly antigenic in mice unless an immunization protocol is performed.
That humoral antibody response could be detected only at a low level against IFNg and at a similar level after IME or ISE, while IME and ISE had distinct kinetic patterns, argues against a role for the humoral antibody immune response in the observed decline of transgene expression. We rather speculate that the rapid turnover of transfected lymphocytes results in the loss of the transgene.
Splenic T cells can be targeted
The previous results urged us to identify the transfected cells. For this purpose, we used the pCMV-Luc plasmid and luciferase was immunolocalized with an antiluciferase antibody on spleen cryosections. With the strong universal CMV promoter, we found luciferase-expressing cells mostly in the white pulp of the spleen where lymphocytes reside ( Figure 6 ). Clusters of transfected cells were evenly distributed in the spleen. Some regions of the spleen had a higher density of those clusters (which are probably responsible for the spot signal previously observed in Figure 2b ), but were apparently not located along the needle track.
Next, we evaluated whether it was possible to target specifically lymphocytes. We chose to focus our attention on T lymphocytes. To be able to immunophenotype transfected cells by flow cytometry, we used a pIL2-EGFP construction in which the EGFP is under the control of the proximal IL2 promoter. Given that IL2 is In
solely expressed by T cells, we expected that EGFP
+ cells to be exclusively T cells. First, we found that to detect EGFP + cells, cell suspensions had to be stimulated for 18 h with PMA+ionomycin (Figure 7a ). This was expected since the IL2 promoter is not constitutive but rather its transcription activity is severely controlled by the T-cell receptor. Furthermore, EGFP + cells were present only within the range of FSC intensity corresponding to lymphocytes. We applied an FSC/SSC morphological gating of lymphocytes and analyzed the EGFP expression within the CD3 + (T cells) and CD19 + (B cells) cell populations. As shown in Figures 7a and b , EGFP + cells were exclusively CD3 + T lymphocytes, and 4.671.1% of total lymphocytes were transfected. This result demonstrates that using a T-cell-specific promoter with this in vivo transfection method allows one to transfer genes that are exclusively expressed by T cells.
One fascinating possibility could be that this method was able to transfect mainly T cells independent of the promoter used. To address this issue, we transfected Ep-TK transgenic mice by ISE with the pCMV-Luc plasmid. In these mice, the thymidine kinase expression is under the control of the human CD4 promoter, the consequence of which is that the thymidine kinase is expressed only in CD4 and CD8 T cells. 28 The treatment with the nucleotide analog GCV leads to the destruction of dividing TKexpressing cells. In order to induce a T-cell proliferation in the spleen, at the time of gene transfer, Ep-TK mice were also immunized by an intrasplenic injection of conalbumin. As shown in Figure 8a , this immunization induced a detectable spleen T-cell proliferation 4 days after the procedure. Indeed, immune responses develop rapidly when the antigen is injected through the intrasplenic route. 29 As expected, a daily GCV treatment that started at day 1 post-transfection partially blocked the anti-conalbumin T-cell response, while the proliferative capacity toward a polyclonal mitogen such as concanavalin A was not affected (Figure 8a ). This indicates that the GCV impaired specifically the immune response toward conalbumin while preserving the rest of the T-cell repertoire intact. More importantly, the GCV treatment, which targets specifically T cells, reduced drastically the luciferase activity in the spleen of immunized mice (Figure 8b ), thus indicating that most of the luciferase activity originated from activated T cells. This experiment thus demonstrates that the ISE with a CMV promoter-bearing plasmid results mostly in the transfection of T cells. This could be because of a poor expression of CMV promoter in the other spleen cell types or to the fact that the electric settings are specifically elective to T cells.
Intrasplenic electroporation does not impair by itself the immune response
To be a suitable immunomodulating strategy, the ISE procedure should not affect by itself the immune responses. In order to avoid an effect eventually triggered by a transgenic protein, we used an empty plasmid. Mice were submitted or not to ISE with an empty vector and immunized (intrasplenic immunization) or not with conalbumin. A group of mice were also left untouched. After 5 days, the mice were killed and spleen cell suspensions were challenged in vitro with conalbumin, or concanavalin A as a positive control, or with thyroglobulin as a negative control. As shown in Figure 9 , the ISE impaired none of the proliferative In vivo gene electrotransfer of spleen cells E Tupin et al responses toward these stimuli. Immunized mice responded equally well to conalbumin regardless of whether they were submitted or not to ISE. The proliferation in response to a mitogen was identical in all groups and none of the groups was able to proliferate in response to thyroglobulin. These results thus indicate that the ISE does not impair a normal immune response. However, further experiments will have to be performed to determine the type of immune response, whether Thl or Th2 is affected or not.
Conclusion
This novel nonviral in vivo method is thus a reliable approach to transfer genetic material to spleen cells. One might speculate that by using the appropriate promoter, any spleen cell type could be targeted. However, our results indicate that T cells are favored with the electric settings used in the present study. We may find other electric parameters that, together with the use of the appropriate promoters, may favor targeting other cells such as B lymphocytes or dendritic cells. The demonstration that this procedure does not impair the immune response by itself is a capital issue. The next step is to evaluate whether plasmids coding for key genes, for instance those encoding for cytokines, can efficiently influence the immune response. IME approach is more likely more adapted to deliver secreted proteins, especially to rescue serum protein deficiencies. However, a possible limitation of IME is that elevated and sustained systemic expression of molecules such as cytokines can induce nonphysiological effects since these molecules are primarily devoted to exert local effects. In this respect, the splenic route, while providing lower concentration of the circulating transgenic protein, might prove to be more efficient for delivering therapeutic molecules to inflammatory site. The transitory nature of the gene transfer could be either a limiting factor or an advantage depending on the pathologic process for which this method is tested. It cannot be used to definitively correct an immune deficit but can likely be used to manipulate an ongoing immune response. Such modulations of the immune response are currently under way in our laboratory. 
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We believe that this gene transfer protocol might be used in many experimental designs and constitute an interesting and simple alternative to existing methods to manipulate locally the immune response. That splenic T cells can be engineered in vivo can provide us with a tool to use them as vectors to deliver molecules at their homing sites.
Materials and methods
Animals
Male and female C57Bl/6 mice 6 to 8-weel-old (IFFACredo) were used for all but one experiment in which we used Ep-TK mice (C57Bl/6 genetic background, kindly provided by Dr D Klatzman; CNRS/UPMC ESA 7087, In
Paris, France). These transgenic mice express the thymidine kinase cDNA under the control of the human CD4 promoter and the murine CD4 minimal proximal enhancer. The pattern of expression of this transgene is restricted to mature peripheral T cells (CD4 + and CD8 + ) and to some NK cells. 28 
Plasmids
Plasmids were prepared by using standard procedures. The plasmid pXL 3031 encoding luciferase (pCMV-Luc) contained the cytomegalovirus (CMV) promoter (nucleotides 229-890 of pcDNA3, Invitrogen) inserted upstream of the coding sequence of the modified cytosolic luc+ luciferase. 30 The pCMV-empty plasmid was obtained from the pCMV-Luc in which the luciferase sequence was excised. The pCMV-SeAP plasmid (pRVX-SeAP2) was obtained by cloning the human SeAP (pSEAP2-Control plasmid; Clontech) downstream of the pCMV in the pcDNA3.1 backbone (Invitrogen). We also used the pIRES2-EGFP backbone (Clontech) in which the (i) the IFNg cDNA sequence was inserted in the multiple cloning site and was under the control of the pCMV (pCMV-IFNg-IRES-EGFP) or (ii) the pCMV was replaced by the IL2 promoter (pIL2-IRES-EGFP). The pIL2 sequence was cloned from genomic C57Bl/6 mouse DNA and the IFNg sequence was cloned from cDNA from C57Bl/6 mouse spleen cells by PCR. For the IL2 promoter, the primers were 5'-TCC CGG GTT TAG GCC AAC ATT CCT TAC-3' and 5'-TGC GGC CGC GAC TTG AGG TCA CTG TGA GG-3' yielding a 1944 bp PCR product (five runs of amplification at 521C and one run at 591C). The PCR products were then digested with SmaI/ NotI restriction enzymes and inserted in the pIRES2-EGFP backbone digested with NruI/NotI restriction enzymes. For the IFNg, the primers were 5'-AGC GGC CGC CAC CAT GAA CGC TAC ACA C-3' and 5'-TGG ATC CTC AGC AGC GAC TC-3' yielding a 488 bp product (five run of amplification at 481C and one run at 561C). The PCR products and the pIRES2-EGFP plasmid were submitted to a digestion with NotI/BamHI restriction enzymes and ligated.
DNA injection and electric pulse delivery
Anesthetized (mixture of xylazine and ketamine) C57Bl/ 6 mice were injected either in the tibial cranial muscle or in the spleen with 15 mg plasmid DNA in 30 ml PBS with a Hamilton (50 ml, 22s/2 00 /2) syringe. A minimum of four mice for each experimental condition was used.
The experimental protocol for IME has been described previously. 19 Briefly, DNA was injected into the tibial cranial muscle, and immediately after injection, transcutaneous electric pulses were applied through two stainless-steel plate electrodes placed at each side of the shaved posterior left limb. A conductive gel was used to ensure an optimal electric contact. Square-wave electric pulses were generated by an ECM 800 electroporator (BTX). The electrical parameters for IME were eight pulses of 20 ms at 200 V/cm at a frequency of 2 Hz, which were the optimal conditions for skeletal muscle gene transfer as determined by Mir et al. 19 For ISE, after anesthesia, a 1 cm laparatomy was performed on the left flank and the spleen was drawn out from the peritoneal cavity. The vasculature of the spleen was clamped and a Hamilton syringe was then deeply inserted into the spleen and the DNA injected while withdrawing the needle. A total of 15 mg of plasmid was diluted in 30 ml of PBS. To prevent leakages and DNA loss, a forceps was applied at the insertion point of the needle while the needle was removed. Immediately after DNA injection, the electrodes were placed on each side of the spleen, the electric pulses were applied, and the clamp was then removed. The spleen was placed back into the peritoneal cavity and the incision was sutured. Various electrical settings were tested, as specified.
Either for ISE or IME, electroporated mice were maintained on a normal chow diet and kept in the standard conditions of our animal department until being killed. Mice were killed by cervical dislocation under anesthesia. Blood was collected by cardiac puncture and allowed to clot. Serum was separated by centrifugation (15 min at 10 000 g) and stored at À801C. Depending on the experiment, spleen, posterior limb skeletal muscles, lymph nodes, thymus, Peyer's patches, and lungs were dissected and snap frozen in liquid nitrogen until use or cultured when indicated. All experiments were approved by the regional ethical committee for animal welfare.
Reporter gene expressions Luciferase
Ex vivo measurements of luciferase activity. Tissue samples were homogenized with an UltraTurax (JankeKunkel, Polylabo) for 5 s in 500 ml of Promega lysis buffer (PLB, Promega) supplemented with aprotinin (ICN Biomedical) at a final concentration of 2 mg/mL. Lysates were then centrifuged at 8000 g for 10 min. Luciferase activity was assessed on 100 ml of supernatant after addition of 100 ml of luciferin (Luciferase Assay Reagent, Promega). The assessment was made immediately after the addition of the substrate by measuring the integration of the light produced during 10 sec with a chemiluminometer (MiniLumat LB 9506, EG&G Berthold). Results were expressed in RLU and represent the light emitted from the 100 ml supernatant aliquot. When comparing different organs, results were expressed in RLU/mg of tissue protein to allow comparison of luciferase expression levels between tissues. The protein content was estimated by the Peterson's method.
In vivo detection of luciferase activity. Mice were submitted to IME or ISE with the pCMV-Luc plasmid. After 2 days, anesthetized mice were injected i.p. with luciferin (3 mg D-luciferin firefly (Euromedex) per mouse) and immediately placed in a light-tight chamber of a low-light imaging system equipped with a CCD camera (DX30 Kappa). Then a gray-scale body-surface reference image was collected under weak illumination. Photons that were emitted from luciferase-expressing cells within the animal 5 min after the luciferin injection and then transmitted through the tissue were collected with 5 min integration time. A pseudocolor image representing light intensity (dark-orange is least intense, white-yellow is most intense) was generated with NIH image 1.62. Gray-scale reference images and pseudocolor images were superimposed.
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Immunohistochemical detection of luciferase. Spleen cryosections, 10 mm thick, were fixed with 4% paraformaldehyde for 10 min. Slides were then first incubated overnight at 41C with a purified goat antiluciferase polyclonal antibody (1 mg/ml; Promega) and next with a biotin-conjugated rabbit anti-goat antibody, which was revealed with an avidin-peroxidase kit (Vectastain ABC kit; Vector) and amino-ethyl-carbazol substrate (Dako).
Phosphatase alkaline activity. Blood samples were collected from cardiac puncture at sacrifice. Human phosphatase assay was performed on 15 ml of serum. Endogenous alkaline phosphatase activity was inhibited by Phospha-light assay buffer (mixture of different alkaline phosphatase inhibitors) and by heat inactivation (651C, 30 min). Detection of secreted human alkaline phosphatase was performed using the commercial chemiluminescence reporter gene assay system (Phospha Light, Tropix).
Light detection was performed at the peak of light emission, that is, 20 min after addition of Phospha-Light reaction buffer in a luminometer Victor (Wallac).
Detection of EGFP positive cells. Spleen cell suspensions were prepared as described 31 6 days after the ISE with the pIL2-IRES-EGFP plasmid, and were plated in six well plates (6 Â 10 6 cells/well). Then, cells were stimulated or not with 50 ng/ml phorbol myristate acetate (PMA) and 500 ng/ml ionomycin for 18 h at 371C. T cells were labeled with an anti-CD3 Cy-conjugated antibody (Becton Dickinson) and B cells with an anti-CD19 PE-conjugated antibody (Becton Dickinson). The FL1 channel was left unused to detect EGFP + cells. Cells were analyzed with a FACSCaliburs (Becton Dickinson). SSC stands for light diffused at right angle (SSC) and FSC for light diffused in the forward direction.
ELISA
Specific IgG antibodies to IFNg and to alkaline phosphatase were titrated in the serum by ELISA. For IFNg assays, microtiter plates (EIA/RIA plate, Costar) were coated overnight at 41C with the capture antibody (1/ 500; Pharmingen OptEIA mouse IFNg set; Becton Dickinson). Recombinant mouse IFNg (rmIFNg; Genzyme) was used as standard (30-2000 pg/ml). For specific IgG, microtiter plates were coated overnight at 41C either with 0.2 mg/ml of rmIFNg (Genzyme) or with 1 mg/ml of human placental alkaline phosphatase (#P3895; Sigma). Purified mouse IgG antibody (#6602398; Beckman Coulter) was used as standard (1-50 mg/ml). After the coating step, plates were washed with PBS-Tween 20 and blocked with PBS-BSA 2%. Serum samples were then added to the wells. After a 2 h incubation, plates were washed and detection antibodies coupled to either HRP (1/250; Pharmingen OptEIA mouse IFNg set, Becton Dickinson) or AKP (1.5 mg/ml anti-mouse IgG; #401262; Calbiochem) were incubated for 1 h. After washing, substrate solution was incubated for 20 min in the dark at room temperature and absorbance was measured with a microplate reader (Molecular Devices, Emax) either at 450 nm for HRPconjugated detecting antibodies or at 405 nm for AKPconjugated antibodies.
Immunization protocols
When specified, mice were immunized with an intrasplenic injection of 20 mg of conalbumin (Sigma) after plasmid DNA electrotransfer.
Proliferation
Spleen cells were prepared as described. 31 Mononuclear cells (250 000/well) were cultured at 371C, with 0.5% CO 2 tension into 96-well flat bottom plates (triplicates) with the indicated stimuli. After 48 h, 1 mCi of 3 Hthymidine was added to each well. After an additional 24 h incubation, incorporated 3 H-thymidine was counted in a Microbeta b-counter. Results are expressed as cpm.
GCV treatement of Ep-TK mice
At day 1 post-transfection, conalbumin-immunized mice were treated or not with ganciclovir (GCV; Clontech). They received 3 mg/day in two ip injections in a total volume of 100 ml. The proliferation of spleen cells and the spleen luciferase activity measurement were performed 4 days post-transfection.
Statistical analysis
Results are expressed as mean7s.e.m. Unpaired nonparametric Mann-Whitney test, ANOVA followed by Fisher's protected least significant difference post hoc tests, and t-tests were performed using Statview 5.0 software (SAS Institute Inc). Differences between groups were considered significant if Po0.05.
